Effect of painless vaginal delivery versus normal vaginal delivery on maternal and neonatal outcomes in pregnant women

Effect of painless vaginal delivery versus normal vaginal delivery on maternal and neonatal outcomes in pregnant women: a clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201508259014N77

Enrollment

168

Registered

2015-09-08

Start date

2015-06-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal delivery. Other obstructed labour

Interventions

Intervention 1: epidural anesthesia with Marcaine 0.125 mg (manufacture by Astrazenca) single dose. Intervention 2: spinal anesthesia with Marcaine 0.125 mg (manufacture by Astrazenca) single dose. In

Prevention

Treatment - Drugs

epidural anesthesia with Marcaine 0.125 mg (manufacture by Astrazenca) single dose

spinal anesthesia with Marcaine 0.125 mg (manufacture by Astrazenca) single dose

combined anesthesia including epidural anesthesia with Marcaine 0.125 mg (manufacture by Astrazenca) single dose and spinal anesthesia with Marcaine 0.125 mg (manufacture by Astrazenca) single dose

Without receiving anesthesia medications

Eligibility

Sex/Gender

Female

Age

15 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) gestational age of 37 weeks or over; (b) being eligible for vaginal delivery. Exclusion criteria: (a) having diabetes, cardiovascular diseases, or intracranial diseases; (b) having gestational diabetes, preeclampsia, or macrosomia; (c) coagulation disorders; (d) dermal infection on the location of epidural anesthesia; (e) non-treated bacteremia.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Measuring the duration of the first and second stages of vaginal delivery. Timepoint: after intervention. Method of measurement: using Friedman curve.;Measuring episiotomy pain. Timepoint: 6 and 12 hours after vaginal delivery. Method of measurement: using visual analog scale (VAS).;) assessing Apgar score. Timepoint: at the first and fifth minutes after birth. Method of measurement: through physical examination.	—

Measure

Time frame

Measuring the duration of the first and second stages of vaginal delivery. Timepoint: after intervention. Method of measurement: using Friedman curve.;Measuring episiotomy pain. Timepoint: 6 and 12 hours after vaginal delivery. Method of measurement: using visual analog scale (VAS).;) assessing Apgar score. Timepoint: at the first and fifth minutes after birth. Method of measurement: through physical examination.

—

Secondary

Measure	Time frame
Assessing hyperthermia. Timepoint: at 4, 8, and 12 hours after vaginal delivery. Method of measurement: using oral thermometer.;Assessing headache. Timepoint: 12 hours after vaginal delivery. Method of measurement: using visual analog scale (VAS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Nahid Radnia

Fatemieh Hospital

n.radnia@umsha.ac.ir+98 81 3828 3939

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026